The AI-native FDA regulatory team
backed by

The AI-native FDA regulatory team
backed by

Our customers
Learn more about how we help deliver the latest medical innovations to patients significantly faster.
Panacea's ex-FDA experience and regulatory expertise has been invaluable. Their AI-powered approach has enabled us to move faster without compromising quality, all with fixed, risk-free pricing. It was a no brainer to choose them as our regulatory partner.

Efraín Torres
CEO, Adialante
Services
From strategy to approval, a unique blend of deep FDA expertise and AI engineers — we deliver results.
Team spotlight
Dr. Jin Zhang, PhD, is a former FDA Lead Reviewer and Team Lead with a Bachelor's and PhD in Biomedical Engineering and Computer Science. Jin has both reviewed and supported hundreds of 510(k)s, Q-Subs, IDEs, De Novos, and PMAs, with experience across all device types. Jin has helped startups and public MedTech companies navigate U.S. regulatory pathways and secure FDA premarket clearances.
Dr. Jin Zhang, PhD
Principal Regulatory Affairs
Track record
We have authored and reviewed filings across all pathways and classes, from strategy all the way to approval.
PMA
Hepatic vascular radioembolization device
De Novo
Radiology AI diagnostic software
510k and DeNovo
First-of-its-kind biology-guided radiotherapy (BgRT)
De Novo
Mechanical circulatory support accessory
510(k)
Neurological surgical planning software
IDE
Radiofrequency ablation vs Radiotherapy clinical study for treating ventricular tachycardia
Why choose us
We are reinventing regulatory consulting with state-of-the-art technology to bring therapies to patients faster.

Other consultants benefit from slower delivery and unclear timelines — same manual work, more billable hours.

At Panacea, we agree on a clear timeline, and work with speed and quality — only paid when we deliver the milestones.